Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents.

ABSTRACT:

Objectives

Guidelines for monitoring of medications frequently used in the gender-affirming care of transgender and gender-diverse (TGD) adolescents are based on studies in adults or other medical conditions. In this study, we aimed to investigate commonly screened laboratory measurements in TGD adolescents receiving gender-affirming hormone therapy (GAHT).

Methods

TGD adolescents were recruited from 4 study sites in the United States before beginning GAHT. Hemoglobin, hematocrit, hemoglobin A1c, alanine transaminase, aspartate aminotransferase, prolactin, and potassium were abstracted from the medical record at baseline and at 6, 12, and 24 months after starting GAHT.

Results

Two-hundred and ninety-three participants (68% designated female at birth) with no previous

SUBMITTER: Millington K 

PROVIDER: S-EPMC11035161 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature